Progression of cortical thinning in Parkinson’s disease
Objective: We sought to validate cortical thickness as an objective biomarker of Parkinson’s disease (PD) progression. Background: Cortical thickness analysis has been proposed as a…The Many Faces of Bradykinesia in Parkinson’s Disease : The Quantitative Analysis from A Keyboard Typing Test
Objective: To explore the characteristics of bradykinesia in PD via a keyboard typing test. Background: Bradykinesia is one of the cardinal symptoms in Parkinson’s disease…Is probable REM sleep behavior disorder a risk factor of impulsive-compulsive behaviors in Parkinson’s disease? PPMI study
Objective: To assess the association of REM sleep behavior disorder (RBD) with the development of impulse compulsive behaviors (ICBs) in patients with early Parkinson’s disease (PD)…How cultural beliefs buffer against suicide in Parkinson’s disease patients with Depression: An Indian Karmic Perspective
Objective: To explore the protective factors associated with suicide from an Indian perspective. Background: The Sanskrit word karma is derived from “Kri” which means “to…Gender-related differences in nonmotor symptoms in the context of subthalamic stimulation in Parkinson’s disease
Objective: To investigate gender differences in quality of life, motor, and nonmotor symptoms (NMS) in patients with Parkinson’s disease (PD) undergoing subthalamic nucleus deep brain…Identifying biomarkers to predict disease progression in early stage Parkinson’s disease patients
Objective: To evaluate the sensitivity of instrumented measures of motor dysfunction and candidate serological markers of disease to predict disease progression in de novo Parkinson’s…Frequency of Impulse Control Disorders and Other Related Behaviors in People with Parkinson’s Disease
Objective: To identify the frequency of impulse control disorders (ICDs) and other related behaviors (i.e. punding, hobbyism, walkabout and dopamine dysregulation syndrome) in people with…Assessing the Safety and Tolerability of ABBV-951 (Foscarbidopa/Foslevodopa) in Advanced Parkinson’s Disease Patients During a 52-Week Phase 3 Study: Study Design and Updated Patient Baseline Characteristics
Objective: To evaluate the local and systemic safety and tolerability of ABBV-951 (foscarbidopa/foslevodopa) delivered 24 h/day as a continuous subcutaneous infusion (CSCI) for up to…Prospective assessment of the lessebo effect in placebo-controlled randomized trials using an expectancy questionnaire
Objective: To prospectively measure the lessebo effect using an expectancy questionnaire (EQ). Background: The presence of a placebo arm in a randomized controlled trial has…Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings
Objective: Evaluate if dose optimization (DO) of apomorphine sublingual film (APL-130277; APL) can achieve improved FULL “ON” response in patients with Parkinson’s disease (PD) and…
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 388
- Next Page »